Aurobindo Pharma Advances In Vaccine Race With The Covaxx Deal: Motilal Oswal
Employees work in the warehouse of an Aurobindo Pharma Ltd. production facility in Jadcherla, India.(Photographer: Prashanth Vishwanathan/Bloomberg)

Aurobindo Pharma Advances In Vaccine Race With The Covaxx Deal: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Aurobindo Pharma Ltd. and Covaxx, a U.S. based company have signed an exclusive agreement to develop, manufacture and commercialize a Covid-19 vaccine (UB-612) for India and United Nations Children’s Fund (UNICEF).

UB-612 is currently in Phase I trials, with Phase II/III to begin in Q1 CY21.

With investments of Rs 1.5 billion under progress to create an annual capacity (to be ready by June 2021) of 480 million doses, the revenue potential from this vaccine could be approximately 280 million U.S. dollar/580 million U.S. dollar in FY22E/FY23E, subject to regulatory approvals.

Click on the attachment to read the full report:

Motilal Oswal Aurobindo Pharma Company Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.